Table 1.
Patient characteristics
| Characteristics | Number | % |
|---|---|---|
| Age | ||
| Median | 68 | |
| Range | 60–85 | |
|
| ||
| ELN Classification | ||
| Favorable | 3 | 14 |
| Intermediate-I | 5 | 24 |
| Intermediate-II | 4 | 19 |
| Adverse* | 9 | 43 |
|
| ||
| Molecular Aberrations | ||
| FLT3-ITD | 1 | 5 |
| NPM1 | 4 | 19 |
| CEBPA | 1 | 5 |
|
| ||
| White blood cell count (×109/L) | ||
| Median | 7.89 | |
| Range | 0.22–134.0 | |
|
| ||
| Secondary AML | ||
| Antecedent hematologic disorder | 10 | 48 |
| Previous treatment for another malignancy | 0 | 0 |
|
| ||
| ECOG Performance Status | ||
| 0 | 1 | 5 |
| 1 | 16 | 76 |
| 2 | 4 | 19 |
Abbreviations: AML, acute myeloid leukemia; CEBPA, CAAT/enhancer-binding protein alpha; ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet; FLT3-ITD, Fms-like tyrosine kinase 3-internal tandem duplication; NPM1, nucleophosmin 1;
*
This cohort included one patient with both del(5) and del(7), three patients with del(5)/−5 and four patients with del(7)/−7. Six patients had complex karyotype.